» Articles » PMID: 15370936

Methylphenidate and Dextroamphetamine Abuse in Substance-abusing Adolescents

Overview
Journal Am J Addict
Specialty Psychiatry
Date 2004 Sep 17
PMID 15370936
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of methylphenidate and dextroamphetamine misuse and abuse was examined in 450 adolescents referred for substance abuse treatment. Twenty three percent reported nonmedical use of these substances and six percent were diagnosed as methylphenidate or dextroamphetamine abusers. Abuse was more common in individuals who were out of school and had an eating disorder. Methylphenidate and dextroamphetamine abuse appears to be much less common than abuse of most other substances. It does occur, however, and parents and schools need to exert greater control over the dispensing of these medications. Physicians are advised to prescribe non-stimulant medications (eg, bupropion) when treating attention deficit hyperactivity disorder in substance-abusing individuals.

Citing Articles

Medical science students' experiences of test anxiety: a phenomenological study.

Badrian M, Bazrafkan L, Shakour M BMC Psychol. 2022; 10(1):187.

PMID: 35906665 PMC: 9336078. DOI: 10.1186/s40359-022-00896-4.


Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls.

Gautam C, Sharma J, Singla M, Tiwana I, Singh H touchREV Endocrinol. 2022; 17(1):33-36.

PMID: 35118444 PMC: 8320008. DOI: 10.17925/EE.2021.17.1.33.


Investigation of Efficacy of Short-Acting Methylphenidate (Ritalin) and Long-Acting (Matoride) on Symptoms of Attention Deficit Hyperactivity Disorder in Children Aged 6-18 Years: A Single-Blind, Randomized Clinical Trial.

Karahmadi M, Saadatmand S, Javad Tarahi M Adv Biomed Res. 2020; 9:18.

PMID: 32695728 PMC: 7365383. DOI: 10.4103/abr.abr_9_20.


Treatment for Substance Use Disorder With Co-Occurring Mental Illness.

Iqbal M, Levin C, Levin F Focus (Am Psychiatr Publ). 2020; 17(2):88-97.

PMID: 31975963 PMC: 6526999. DOI: 10.1176/appi.focus.20180042.


A Review of Psychostimulants for Adults With Depression.

Pary R, Scarff J, Jijakli A, Tobias C, Lippmann S Fed Pract. 2019; 32(Suppl 3):30S-37S.

PMID: 30766117 PMC: 6375494.